Skip to main content
    S

    Sellas Life Sciences Group Inc (SLS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.41
    +0.48 (+4.02%)

    Market Cap: $2.51B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(22/39)
    Avg Surprise
    -175.97%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.05
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.06+9.1%
    60d ago$-0.06+9.1%
    30d ago$-0.06+9.1%
    7d ago$-0.06+9.1%
    Current$-0.05
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.04
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.04---
    Sep 26EST
    		-$-0.05---
    Jun 26
    Reported Aug 11
    		$-0.05$-0.04-25.00%Miss+28.6%
    Mar 26
    Reported May 12
    		$-0.05$-0.07+30.43%Beat+30.4%
    Dec 25
    Reported Mar 19
    		$-0.05$-0.06+16.67%Beat+37.5%
    Sep 25
    Reported Nov 12
    		$-0.06$-0.08+25.00%Beat+40.0%
    Jun 25
    Reported Aug 12
    		$-0.07$-0.08+12.50%Beat+46.2%
    Mar 25
    Reported May 13
    		$-0.07$-0.11+36.36%Beat+66.7%
    Dec 24
    Reported Mar 20
    		$-0.08$-0.11+25.02%Beat+68.0%
    Sep 24
    Reported Nov 13
    		$-0.10$-0.13+23.08%Beat+69.7%
    Jun 24
    Reported Aug 13
    		$-0.13$-0.17+23.53%Beat+58.1%
    Mar 24
    Reported May 14
    		$-0.21$-0.16-31.25%Miss+55.3%
    Dec 23
    Reported Mar 28
    		$-0.25$0.09-377.78%Miss+41.9%
    Sep 23
    Reported Nov 9
    		$-0.33$0.02-1750.00%Miss+2.9%
    Jun 23
    Reported Aug 10
    		$-0.31$-0.35+11.43%Beat+26.2%
    Mar 23
    Reported May 11
    		$-0.47$-0.29-62.07%Miss-11.9%
    Dec 22
    Reported Mar 16
    		$-0.43$-0.32-34.38%Miss-2.4%
    Sep 22
    Reported Nov 14
    		$-0.34$-0.39+12.82%Beat+24.4%
    Jun 22
    Reported Aug 11
    		$-0.42$-0.37-13.51%Miss-40.0%
    Mar 22
    Reported May 12
    		$-0.42$-0.42+0.00%Beat-162.5%
    Dec 21
    Reported Mar 31
    		$-0.42$-0.41-2.44%Miss-50.0%
    Sep 21
    Reported Nov 12
    		$-0.45$-0.34-32.35%Miss+15.1%
    Jun 21
    Reported Aug 12
    		$-0.30$-0.39+23.08%Beat+52.4%
    Mar 21
    Reported May 13
    		$-0.16N/A+55.56%Beat+74.6%
    Dec 20
    Reported Mar 23
    		$-0.28$-0.28+0.00%Beat+81.8%
    Sep 20
    Reported Nov 13
    		$-0.53$-0.34-55.88%Miss+44.8%
    Jun 20
    Reported Aug 13
    		$-0.63$-0.64+1.56%Beat+89.8%
    Mar 20
    Reported May 14
    		$-0.63$-0.68+7.35%Beat+93.5%
    Dec 19
    Reported Mar 13
    		$-1.54$-0.72-113.89%Miss+81.9%
    Sep 19
    Reported Nov 14
    		$-0.96$-1.00+4.00%Beat+96.4%
    Jun 19
    Reported Aug 14
    		$-6.19$-9.00+31.22%Beat+90.2%
    Mar 19
    Reported May 15
    		$-9.71$-10.25+5.27%Beat+88.4%
    Dec 18
    Reported Mar 22
    		$-8.50$-11.75+27.66%Beat+82.8%
    Sep 18
    Reported Nov 15
    		$-26.50$-20.25-30.86%Miss+11.7%
    Jun 18
    Reported Aug 15
    		$-63.00$-51.50-22.33%Miss+80.9%
    Mar 18
    Reported Apr 13
    		$-83.50$-46.50-79.57%Miss+87.6%
    Dec 17
    Reported Mar 15
    		$-49.50$-1.06-4569.81%Miss+93.3%
    Sep 17
    Reported Nov 9
    		$-30.00N/A+86.67%Beat-
    Jun 17
    Reported Aug 14
    		$-330.00$-270.00-22.22%Miss-
    Mar 17
    Reported May 10
    		$-675.00$-330.00-104.55%Miss-
    Dec 16
    Reported Mar 15
    		$-735.00$-780.00+5.77%Beat-

    Key Metrics

    Valuation
    P/E Ratio-59.46EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-39.60%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio18.83xQuick Ratio18.83x
    Trading Statistics
    Beta2.57Avg Volume5.51M
    52-Week High$15.8852-Week Low$1.39

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$11.69
    SMA 20$11.66
    SMA 50$12.46
    SMA 200$8.10
    EMA 10$11.77
    EMA 20$11.87
    EMA 50$11.95
    EMA 200$8.81

    MACD

    Line: -0.18Signal: -0.27Hist: 0.10

    ADX

    ADX: 13.8+DI: 23.3-DI: 14.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down88.0
    PSAR$10.71

    Bollinger Bands

    Upper Band$12.30
    Lower Band$11.02
    %B Position1105%(Upper)
    Band Width1.08

    RSI (14-Day)

    Neutral
    54.4

    Momentum Oscillators

    Stoch %K68.0
    Stoch %D50.2
    Williams %R-14.7
    ROC (10d)7.8%
    Momentum0.90
    CCI (20d)241.5
    MFI (14d)56.3

    Volatility Measures

    ATR (14d)$0.80(6.5%)
    StdDev (20d)0.32
    Hist Vol57.5%(High)

    Volume Flow

    VWAP$12.27
    OBV241.9M
    AD Line110.0M
    CMF (20d)0.183

    Volume Metrics

    Avg Vol (20d)5.3M
    Vol Ratio1.2x
    VWMA (20d)$11.69

    Pivot Points

    R3$12.89
    R2$12.51
    R1$12.22
    Pivot Point$11.85
    S1$11.56
    S2$11.18
    S3$10.89

    Advanced Oscillators

    TSI-6.14
    Ultimate Osc61.9
    KST-81.75

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0$0$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0$0$0
    Operating Expenses$10.63M$9.25M$8.26M$7.08M$6.87M$6.06M$6.92M$7.33M$7.62M$9.64M$8.18M$9.36M
    R&D$6.27M$5.13M$4.73M$4.22M$3.87M$3.21M$4.44M$4.36M$5.19M$5.11M$5.10M$5.81M
    SG&A$4.36M$4.12M$3.52M$2.87M$3.00M$2.86M$2.48M$2.97M$2.44M$4.53M$3.08M$3.55M
    Operating Income$-10,629,000$-9,252,000$-8,255,000$-7,083,000$-6,873,000$-6,063,000$-6,918,000$-7,329,000$-7,621,000$-9,645,000$-8,177,000$-9,361,000
    Interest Income$1.02M$845,000$597,000$292,000$272,000$250,000$181,000$221,000$151,000$79,000$0$94,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-9,605,000$-8,407,000$-7,658,000$-6,791,000$-6,601,000$-5,813,000$-6,737,000$-7,108,000$-7,470,000$-9,566,000$-8,136,000$-9,267,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-9,605,000$-8,407,000$-7,658,000$-6,791,000$-6,601,000$-5,813,000$-6,737,000$-7,108,000$-7,470,000$-9,566,000$-8,136,000$-9,267,000
    EBITDA$-10,475,000$-9,099,000$-8,101,000$-7,083,000$-6,724,000$-5,916,000$-6,770,000$-7,329,000$-7,621,000$-9,507,000$-8,177,000$-9,239,000
    EBIT$-10,629,000$-9,252,000$-8,255,000$-7,083,000$-6,873,000$-6,063,000$-6,918,000$-7,329,000$-7,621,000$-9,645,000$-8,177,000$-9,361,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SLS

    News

    SLS Stock Slides As GPS Trial Disclosure Probe Escalates

    SELLAS Life Sciences Group Inc. (SLS) stock has dropped over 12% following news of a Pomerantz LLP investigation into potential securities fraud. The probe focuses on the company's handling of Phase 3 trial data for its...

    StocksToTrade•10/16/26•Neutral

    SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH

    Shares of Sellas Life Sciences (SLS) surged over 3% overnight as retail investors speculate that the company's large booth at the American Society of Hematology's (ASH) annual meeting could indicate an impending buyout...

    Stocktwits•10/11/26•Somewhat-Bullish

    SELLAS Life Sciences Group, Inc. (SLS) options chain

    This article provides an options chain for SELLAS Life Sciences Group, Inc. (SLS), showing its stock price, trading activity...

    Yahoo Finance Australia•10/7/26•Neutral

    SELLAS Life Sciences Group, Inc. (RXK3.F) stock price, news, quote and history

    This page provides an overview of SELLAS Life Sciences Group, Inc. (RXK3.F) stock, including its current price, news, and historical data. The stock is trading at 10.00 EUR, up 0.20%...

    Yahoo Finance UK•10/7/26•Neutral

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

    Pomerantz LLP is investigating potential securities fraud claims against SELLAS Life Sciences Group, Inc. (NASDAQ...

    FinancialContent•10/6/26•Bearish

    SLS Valuation and Fair Value

    P/E
    -59.5x
    P/B
    17.1x
    See GNG's fair value

    SLS Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -39.6%

    SLS Competitors

    CompanyTicker
    Zai Lab LtdZLAB
    Beam Therapeutics IncBEAM
    Clover Health Investments CorpCLOV
    Maravai Lifesciences Holdings IncMRVI
    Guardian Pharmacy Services, Inc.GRDN
    MBX Biosciences, Inc. Common StockMBX
    Nurix Therapeutics IncNRIX
    HUTCHMED DRCHCM

    Sector: Healthcare

    SLS Bull Case vs Bear Case

    Bull case

    • SLS beat EPS estimates in 87.5% of its last 8 reported quarters.

    Bear case

    • SLS's quarterly revenue changed -82.5% year over year.

    SLS Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    18.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.05
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About SLS

    Does SLS pay dividends?

    Sellas Life Sciences Group Inc (SLS) does not currently pay a regular dividend.

    What is SLS's market cap?

    Sellas Life Sciences Group Inc (SLS) has a market capitalization of $2.51B with a current stock price of $12.41.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In